Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02517827
Other study ID # UHZ_RASA_PESTO_1.0
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 1, 2017
Est. completion date December 2021

Study information

Verified date August 2018
Source Herz-Zentrums Bad Krozingen
Contact Aljoscha Rastan, MD
Phone 004976334024913
Email aljoscha.rastan@universitaets-herzzentrum.de
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The endovascular therapy prevailed in nearly all regions of peripheral artery disease over open surgery techniques. However, in treatment of the common femoral artery vascular surgery is still the gold standard of therapy. One-year patency rates are between 90% and 95%. Today, only in selected cases an endovascular procedure for common femoral artery diseases is recommended.

The primary objective of this study is to compare the performance of directional atherectomy and drug-coated balloon angioplasty over vascular surgery in common femoral artery lesions in a prospective, multi-center, randomized clinical trial.


Description:

Multicenter, prospective, randomized study to be conducted in centers in Europe. A total of 260 subjects will be entered into the study and will be randomized on a 1:1 basis to either directional atherectomy and drug coated balloon angioplasty (optional with stentimplantation), and surgical endarterectomy for treatment in symptomatic (Rutherford-Becker class 2 to 4) common femoral artery disease. All subjects will undergo repeat duplex-ultrasound measurements 6, 12, and 24 months to assess the primary endpoint of Binary Restenosis. Follow-up visits are scheduled 6, 12, and 24 months.


Recruitment information / eligibility

Status Recruiting
Enrollment 306
Est. completion date December 2021
Est. primary completion date December 2019
Accepts healthy volunteers No
Gender All
Age group 21 Years to 85 Years
Eligibility Inclusion Criteria:

1. Subject must be between 21 and 85 years old;

2. Female of childbearing potential must have a negative pregnancy test within 10 days prior to index procedure and utilize reliable birth control until completion of the 12-month angiographic evaluation;

3. Clinical diagnosis of symptomatic peripheral artery disease defined by Rutherford 2, 3, or 4;

4. Common femoral artery (CFA) stenosis (including CFA bifurcation) >70% (visual estimate) or occlusion; Additional non-target lesion(s) in remaining non-target vessel(s), except ipsilateral iliac arteries, can be treated at the physician´s discretion;

5. At least one vessel outflow (infrapopliteal arteries) to the foot (without stenosis >50%).

6. Endovascular Procedure: successful target lesion crossing of the guidewire (guidewire located intraluminally);

7. Non-target lesion interventions (TASC A and B) to restore adequate blood flow, in the same index procedure are allowed. This intervention must be prior to the treatment of the study lesion and successful;

8. Willing to comply with the specified follow-up evaluation;

9. Written informed consent prior to any study procedures.

Exclusion Criteria:

1. Ipsilateral significant (>50%) stenosis of the iliac arteries.

2. Significant (>50%) stenosis of all infrapopliteal arteries, no patent artery to the foot.

3. Angiographic evidence of thrombus within target vessel;

4. Thrombolysis within 72 hours prior to the index procedure;

5. In-Stent restenosis or restenosis of the native common femoral artery.

6. Aneurysm in the abdominal aorta or iliac arteries;

7. Concomitant hepatic insufficiency, thrombophlebitis, deep venous thrombus, coagulation disorder or receiving immunosuppressant therapy;

8. Recent MI or stroke < 30 days prior to the index procedure;

9. Life expectancy less than 24 months;

10. Known or suspected active infection at the time of the index procedure;

11. Known or suspected allergies or contraindications to aspirin, clopidogrel bisulfate (Plavix) and ticlopidine (Ticlid), heparin, or contrast agent;

12. Any significant medical condition which, in the investigator´s opinion, may interfere with the subject´s optimal participation in the study;

13. The subject is currently participating in another investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the endpoints of this study.

Study Design


Intervention

Device:
Atherectomy and paclitaxel-coated balloon angioplasty
Directional atherectomy and paclitaxel-coated balloon angioplasty (optional with stentimplantation) of the common femoral artery
Procedure:
Open, surgical endarterectomy
open, surgical endarterectomy of the common femoral artery

Locations

Country Name City State
Germany Universitäts-Herzzentrum Freiburg - Bad Krozingen Bad Krozingen

Sponsors (2)

Lead Sponsor Collaborator
Herz-Zentrums Bad Krozingen Medtronic

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Other Rutherford-Becker class Change in Rutherford-Becker class 6, 12, and 24 months
Primary Primary patency Primary patency of the common femoral artery defined as freedom from target lesion restenosis (luminal narrowing of =50%) detected with duplex-ultrasound. The definition of a 50% restenosis is based on the peak systolic velocity ratio >2.4. 12 month
Secondary Primary patency Primary patency of the common femoral artery defined as freedom from target lesion restenosis (luminal narrowing of =50%) detected with duplex-ultrasound. The definition of a 50% restenosis is based on the peak systolic velocity ratio >2.4. 24 month
Secondary target lesion revascularisation Need for target lesion revascularisation after index procedure 6, 12, and 24 month
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05712395 - The Effects of a Novel, Non-ischemic and Pain-free Exercise Intervention in Peripheral Artery Disease N/A
Active, not recruiting NCT04534257 - Prospective Registry to Investigate the Safety and Efficacy of the Treatment With the Selution Sirolimus Drug Coated Balloon in TASC C and D Atheroma-occlusive Infra-Inguinal Disease in Patients With Chronic Limb Threatening Ischemia From Singapore N/A
Recruiting NCT04511234 - Sirolimus Coated Balloon Versus Standard Balloon for SFA and Popliteal Artery Disease N/A
Recruiting NCT03506633 - Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients N/A
Active, not recruiting NCT03506646 - Dietary Nitrate Supplementation and Thermoregulation N/A
Completed NCT02554266 - Registry Investigating the Clinical Use and Safety of the Lutonix Drug Coated Balloon for Treatment of BTK Arteries
Completed NCT03921905 - Peripheral Artery Disease in Patients With Stable Coronary Artery Disease in General Practice: Prevalence, Management and Clinical Outcomes.
Not yet recruiting NCT06369350 - Vitamin B6 on Exercise Pressor Reflex on Leg Ischemia-reperfusion Early Phase 1
Recruiting NCT04545268 - Prehabilitation for Cardiac Surgery in Patients With Reduced Exercise Tolerance N/A
Recruiting NCT02389023 - Comparison of Prevena Negative Pressure Incision Management System vs. Standard Dressing After Vascular Surgery N/A
Completed NCT02542267 - In-Stent Restenosis Post-Approval Study N/A
Completed NCT02563535 - Evaluation of the Use of ACOTEC Drug-Eluting Balloon Litos ® in Below-The-Knee Arteries to Treat Critical Limb Ischemia Phase 4
Completed NCT02522884 - Tack Optimized Balloon Angioplasty Study of the Tack Endovascular System™ in Femoropoliteal Arteries N/A
Completed NCT02539940 - Elutax-SV Drug-eluting Balloons for Below-the-knee Treatment
Completed NCT02145065 - First-in-man Evaluation of a Novel, Microcrystalline Paclitaxel Coated Balloon for Treatment of Femoropopliteal Artery Disease (PAX-r) N/A
Completed NCT02262949 - A Prospective Study of the Bard® LifeStent® Solo Vascular Stent System N/A
Completed NCT02228564 - BARD® Study of LIFESTREAM™ Balloon Expandable Covered Stent Treating Iliac Arterial Occlusive Disease N/A
Completed NCT01743872 - Optical Imaging Measurement of Intravascular Solution Efficacy Trial N/A
Recruiting NCT01424020 - Walking Estimated Limitation Calculated by History - Study 2 Phase 4
Active, not recruiting NCT01597453 - NOR-SYS: The Norwegian Stroke in the Young Study N/A